ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE, LOCALLY ADVANCED OR METASTATIC BREAST CANCER
Clinical trials for ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE, LOCALLY ADVANCED OR METASTATIC BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE, LOCALLY ADVANCED OR METASTATIC BREAST CANCER trials appear
Sign up with your email to follow new studies for ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE, LOCALLY ADVANCED OR METASTATIC BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for advanced breast cancer patients as trial tests Next-Generation hormone therapy
Disease control OngoingThis study is testing an experimental drug called giredestrant for people with a specific type of advanced breast cancer that has grown despite one or two prior treatments. It compares giredestrant to the hormone therapy a doctor would normally choose. The main goal is to see if …
Matched conditions: ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE, LOCALLY ADVANCED OR METASTATIC BREAST CANCER
Phase: PHASE2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Apr 02, 2026 04:26 UTC
-
New hope for advanced breast cancer: major trial tests promising drug combo
Disease control OngoingThis large Phase 3 trial is testing whether a new drug called giredestrant, when combined with palbociclib, works better than the current standard treatment (letrozole + palbociclib) for people with a specific type of advanced breast cancer. The study involves 992 patients whose …
Matched conditions: ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE, LOCALLY ADVANCED OR METASTATIC BREAST CANCER
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Mar 27, 2026 12:38 UTC